OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Dapagliflozin versus empagliflozin in patients with chronic kidney disease
Hilmi Alnsasra, Gal Tsaban, Adam Solomon, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Hilmi Alnsasra, Gal Tsaban, Adam Solomon, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Showing 7 citing articles:
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis
Phil McEwan, Marco Hafner, Vivekanand Jha, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 1407-1416
Open Access | Times Cited: 4
Phil McEwan, Marco Hafner, Vivekanand Jha, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 1407-1416
Open Access | Times Cited: 4
Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database
Annamaria Mascolo, Alessia Zinzi, Mario Gaio, et al.
Pharmacological Reports (2024)
Closed Access | Times Cited: 1
Annamaria Mascolo, Alessia Zinzi, Mario Gaio, et al.
Pharmacological Reports (2024)
Closed Access | Times Cited: 1
A novel HPLC method for the simultaneous determination of empagliflozin and dapagliflozin: Development, validation, robustness testing and greenness assessment
Eleftheria Kladi, Maria Zerva, Yannis Dotsikas
Arhiv za farmaciju (2024) Vol. 74, Iss. 3, pp. 267-280
Open Access
Eleftheria Kladi, Maria Zerva, Yannis Dotsikas
Arhiv za farmaciju (2024) Vol. 74, Iss. 3, pp. 267-280
Open Access
Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease with or without Albuminuria
Motoki Odawara, Hiroshi Nishi, Satoshi Kodera, et al.
Clinical Journal of the American Society of Nephrology (2024) Vol. 20, Iss. 1, pp. 50-61
Closed Access
Motoki Odawara, Hiroshi Nishi, Satoshi Kodera, et al.
Clinical Journal of the American Society of Nephrology (2024) Vol. 20, Iss. 1, pp. 50-61
Closed Access
Dapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis
Carlos U. Vargas-Ramírez, Víctor Posadas-Posadas, Renata Ochoa-Précoma, et al.
Diabetology International (2024) Vol. 16, Iss. 1, pp. 65-77
Closed Access
Carlos U. Vargas-Ramírez, Víctor Posadas-Posadas, Renata Ochoa-Précoma, et al.
Diabetology International (2024) Vol. 16, Iss. 1, pp. 65-77
Closed Access
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes
Noomi Vainer, Viktor Rotbain Curovic, Carsten Utoft Niemann, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 9, pp. 617-629
Open Access
Noomi Vainer, Viktor Rotbain Curovic, Carsten Utoft Niemann, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 9, pp. 617-629
Open Access
Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model
Roberto Ravasio, Andrea Marcellusi, Luca De Nicola
Global & Regional Health Technology Assessment (2024) Vol. 11, Iss. 1, pp. 231-238
Open Access
Roberto Ravasio, Andrea Marcellusi, Luca De Nicola
Global & Regional Health Technology Assessment (2024) Vol. 11, Iss. 1, pp. 231-238
Open Access
